65 research outputs found

    Service Learning in Guatemala: Using Qualitative Content Analysis to Explore an Interdisciplinary Learning Experience Among Students in Health Care Professional Programs

    Get PDF
    What is the experience of interprofessional collaboration as a nursing, occupational, or physical therapy health care student taking part in a weeklong service-learning experience? Interprofessional collaboration among health care professionals yields improved patient outcomes, yet many students in health care programs have limited exposure to interprofessional collaboration in the classroom and in clinical and service-learning experiences. This practice gap implies that students enter their professions without valuing interprofessional collaboration and the impact it has on promoting positive patient outcomes. The aim of this study was to describe the interprofessional experiences of students in health care professional programs as they collaborated to provide health care to Guatemalan citizens over a 7-day period

    The Grizzly, February 10, 1989

    Get PDF
    Ursinus Seeks Mid-States Reaccreditation • Heck Beats Traffic Blahs • Letter: Doughty Expresses Doubts • U.C. Salutes French Bicentennial • Medieval Fest Needs You • Ginsberg to Give Revolutionary Forum • Casa Maria: Muy Bien • de la Hoya Happy • Ursinus Slays F & M • U.C. Aims for Title • O\u27Malley Leaps to Nationals • Women\u27s Indoor Inspiring • U.C. Fields Strong Squad • A\u27Bears Peaking at Right Time • Scholarships to Scotland • Guess Who\u27s Coming for Dinner? • His Cheating Makes Twice the Test for You • Hallinger Argues for Proposal 42: Academics Before Athlete • Greenstein Grabs Grim \u27Just Right\u27 • Valentine No-No\u27s • From America With Love: Students Flock to U.C.https://digitalcommons.ursinus.edu/grizzlynews/1228/thumbnail.jp

    Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)

    Get PDF
    Circulating protein markers were assessed in patients with colorectal cancer (CRC) treated with cetuximab in CALGB 80203 to identify prognostic and predictive biomarkers. Patients with locally advanced or metastatic CRC received FOLFOX or FOLFIRI chemotherapy (chemo) or chemo in combination with cetuximab. Baseline plasma samples from 152 patients were analyzed for six candidate markers [epidermal growth factor (EGF), heparin-binding EGF (HBEGF), epidermal growth factor receptor (EGFR), HER2, HER3, and CD73]. Analyte levels were associated with survival endpoints using univariate Cox proportional hazards models. Predictive markers were identified using a treatment-by-marker interaction term in the Cox model. Plasma levels of EGF, HBEGF, HER3, and CD73 were prognostic for overall survival (OS) across all patients (KRAS mutant and wild-type). High levels of EGF predicted for lack of OS benefit from cetuximab in KRAS wild-type (WT) patients (chemo HR = 0.98, 95% CI = 0.74-1.29; chemo+cetuximab HR = 1.54, 95% CI = 1.05-2.25; interaction P = 0.045) and benefit from cetuximab in KRAS mutant patients (chemo HR = 1.72, 95% CI = 1.02-2.92; chemo+cetuximab HR = 0.90, 95% CI = 0.67-1.21; interaction P = 0.026). Across all patients, higher HER3 levels were associated with significant OS benefit from cetuximab treatment (chemo HR = 4.82, 95% CI = 1.68-13.84; chemo+cetuximab HR = 0.95, 95% CI = 0.31-2.95; interaction P = 0.046). CD73 was also identified as predictive of OS benefit in KRAS WT patients (chemo HR = 1.28, 95% CI = 0.88-1.84; chemo+cetuximab HR = 0.60, 95% CI = 0.32-1.13; interaction P = 0.049). Although these results are preliminary, and confirmatory studies are necessary before clinical application, the data suggest that HER3 and CD73 may play important roles in the biological response to cetuximab

    The Lantern Vol. 58, No. 2, Summer 1991

    Get PDF
    • We All Fall Up • Clerical Nightmares • The Brass Bed • Mon Amour • The Lady of J. Alfred Prufrock • Forbidden Places • Edge of the Dance • Crystal World • Saturday, July 12, 1978, 4:59 pm • Of You I Think • Just Another Statistic • A 16Wordina16 Word in a 4.99 Trashcan • Souvenir • The Jester • Against a Rock • I Wish I Were a Fish • Too Small, Too Weak • Somewheres in N.Y.C. • Stuck Up • Patterns • I Should Tell You Now • Me, Tommy, and Miss May • Two Hands • All-Natural, Organically Grown Macadamia Butter • Irony of a Suburban Deathhttps://digitalcommons.ursinus.edu/lantern/1138/thumbnail.jp

    Blood�based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)

    Get PDF
    Circulating protein markers were assessed in patients with colorectal cancer (CRC) treated with cetuximab in CALGB 80203 to identify prognostic and predictive biomarkers. Patients with locally advanced or metastatic CRC received FOLFOX or FOLFIRI chemotherapy (chemo) or chemo in combination with cetuximab. Baseline plasma samples from 152 patients were analyzed for six candidate markers [epidermal growth factor (EGF), heparin�binding EGF (HBEGF), epidermal growth factor receptor (EGFR), HER2, HER3, and CD73]. Analyte levels were associated with survival endpoints using univariate Cox proportional hazards models. Predictive markers were identified using a treatment�by�marker interaction term in the Cox model. Plasma levels of EGF, HBEGF, HER3, and CD73 were prognostic for overall survival (OS) across all patients (KRAS mutant and wild�type). High levels of EGF predicted for lack of OS benefit from cetuximab in KRAS wild�type (WT) patients (chemo HR = 0.98, 95% CI = 0.74–1.29; chemo+cetuximab HR = 1.54, 95% CI = 1.05–2.25; interaction P = 0.045) and benefit from cetuximab in KRAS mutant patients (chemo HR = 1.72, 95% CI = 1.02–2.92; chemo+cetuximab HR = 0.90, 95% CI = 0.67–1.21; interaction P = 0.026). Across all patients, higher HER3 levels were associated with significant OS benefit from cetuximab treatment (chemo HR = 4.82, 95% CI = 1.68–13.84; chemo+cetuximab HR = 0.95, 95% CI = 0.31–2.95; interaction P = 0.046). CD73 was also identified as predictive of OS benefit in KRAS WT patients (chemo HR = 1.28, 95% CI = 0.88–1.84; chemo+cetuximab HR = 0.60, 95% CI = 0.32–1.13; interaction P = 0.049). Although these results are preliminary, and confirmatory studies are necessary before clinical application, the data suggest that HER3 and CD73 may play important roles in the biological response to cetuximab

    The Grizzly, December 3, 1990

    Get PDF
    Wismer Hall to be Renovated by Next Fall • Quad Intruder Returns • Politics Honors Projects • Foreign Policy and the Press • Ursinus Offers St. Joseph\u27s Post-MBA Certificates • Dance Marathon Planned • Crazy Toys • Holiday Messages Encouraged • Exam Schedule • Mixed Up • Jane\u27s Addiction Concert Review • European Old Master Prints • At the Playhouse • Attention Skiers • Edie Brickell Reviewed • In the Spotlight • Swimmers Host Double-Header Weekend • Lady Hoopsters Shoot for Title • Are We Going to War? • Why are We Really There? • Hey! Who\u27s the New Guy? • Brain in Brief • Bonnie and SAM (not Clyde)https://digitalcommons.ursinus.edu/grizzlynews/1266/thumbnail.jp
    • …
    corecore